Non-Small Cell Lung Cancer Coverage from Every Angle

FDA Brief: Zenocutuzumab Granted Fast Track Designation for NRG1 Fusion Cancers

By: JNCCN 360 Staff
Posted: Wednesday, January 20, 2021

On January 7, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to zenocutuzumab for the treatment of patients with metastatic solid tumors with neuregulin 1 (NRG1) gene fusions that progressed from a standard-of-care therapy.

The drug is currently being investigated in the currently enrolling phase I/II eNRGy trial of patients with NRG1 gene fusion–positive solid tumors (eg, non–small cell lung cancer, breast cancer, and ovarian cancer).

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.